Helping You Build Wealth With Honest Research
Since 1996. Read On...

MEMBER'S LOGIN

MEMBER'S LOGINX

     
Invalid Username / Password
   
     
   
     
 
Invalid Captcha
   
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

Revealed
India's Third Giant Leap

This Could be One of the Biggest Opportunities for Investors




Important: We hate spam as much as you do. Check out our Privacy Policy and Terms Of Use.
By submitting your email address, you also sign up for Profit Hunter, a daily newsletter from Equitymaster
covering exciting investing ideas and opportunities in India.

AD

Indian markets open in green
Tue, 6 Oct 09:30 am

The major Asian stock markets have opened the day in green. Stock markets in Indonesia, Singapore and Japan are trading up by 2.1%, 1% and 0.9% respectively. The major stock indices in Europe and US markets ended their previous session on an encouraging note. The rupee is trading at 65.26 per US dollar.

Indian stock markets have opened the day on a positive note. BSE-Sensex is trading higher by 92 points (up 0.3%) and NSE-Nifty is trading higher by 21 points (up 0.2%). Both S&P BSE Midcap and S&P BSE Smallcap, have too opened firm. Both BSE Mid-Cap and BSE Small-Cap are trading higher by 0.3% and 0.6% respectively. Among the sectoral indices, barring stocks from banking sector, major sectoral indices have opened the day in green. Stocks from pharmaceutical and telecommunication are in maximum demand.

As per an article in Livemint, Housing Development Finance Corporation (HDFC) has reduced its prime lending rate by 0.25%. The reduction in the lending rates will be effective from today. The reduction will bring down the effective home loan rates for new customers to 9.65% per annum. Moreover with the start of the festive season, company was induced to cut the lending rates in order to be more competitive. Other, banks such as Axis Bank and ICICI Bank have already reduced the lending rate by 0.35% following the RBI's policy. The cut in the lending rate is followed by the RBI's policy decision on 29th September to reduce the benchmark repo rate by 0.50%. So should your investments follow interest rate cycle? In one of our recent 5-minute wrap up edition, Madhu has discussed about this.

Few months back, the European Commission had banned the sale of 700 pharmaceutical products which were clinically tested by GVK Biosciences. Since then there has been delay in meeting to decide upon this decision. Recently, in a meeting India's Prime Minister Narendra Modi, had discussion with the German chancellor over the ban imposed on the pharma products. Reportedly he urged the German chancellor to ensure that the right decision was made by the regulator in this regard. According to the data provided by Pharmaceutical Promotion Export Council, India could lose about USD$ 1-1.2 bn worth of drug exports because of the decision taken by the European Commission to ban the drugs. Now such bans would also have some impact on the pharma companies' revenues and margins. Infact, we had written about this in of our edition of 5 minute premium

For information on how to pick stocks that have the potential to deliver big returns, download our special report now!

View all commentaries | Archives

Read the latest Market Commentary


Equitymaster requests your view! Post a comment on "Indian markets open in green". Click here!

  
ABOUT EQUITYMASTER

Since 1996, Equitymaster has been the source for honest and credible opinions on investing in India. With solid research and in-depth analysis Equitymaster is dedicated towards making its readers- smarter, more confident and richer every day. Here's why hundreds of thousands of readers spread across more than 70 countries Trust Equitymaster.

PREMIUM PRODUCTS
QUICK LINKS
POPULAR TOPICS
TRENDING TOPICS
FREE NEWSLETTERS
EQUITYMASTER SUPPORTS
  • HelpYourNGO
  • You Tube
  • Linkedin
  • Twitter
  • Telegram
  • Google Play

Copyright © Equitymaster Research Private Limited (formerly Equitymaster Agora Research Private Limited).

Whitelist | Refer | Terms | Privacy | Contact | About | Sitemap

Phone +91-9136015013

Equitymaster Research Private Limited (formerly Equitymaster Agora Research Private Limited) (Research Analyst)
SEBI (Research Analysts) Regulations 2014, Registration No. INH000000537.

103, Regent Chambers, Above Status Restaurant, Nariman Point, Mumbai - 400 021. India.
Telephone: +91-22-61434055. Email: info@equitymaster.com. Website: www.equitymaster.com.
CIN:U74999MH2007PTC175407

Name of the Compliance & Grievance Officer: Ms Sonal Ramachandran
Telephone: +91-22-61434003 | Email: compliance@equitymaster.com

LEGAL DISCLAIMER:
Investment in securities market are subject to market risks. Read all the related documents carefully before investing.
Registration granted by SEBI and certification from NISM in no way guarantee performance of the intermediary or provide any assurance of returns to investors.

All rights reserved. Any act of copying, reproducing or distributing this newsletter whether wholly or in part, for any purpose without the permission of Equitymaster is strictly prohibited and shall be deemed to be copyright infringement.

Equitymaster Research Private Limited (formerly Equitymaster Agora Research Private Limited) (Research Analyst) bearing Registration No. INH000000537 (hereinafter referred as 'Equitymaster') is an independent equity research Company. Equitymaster is not an Investment Adviser. Information herein should be regarded as a resource only and should be used at one's own risk. This is not an offer to sell or solicitation to buy any securities and Equitymaster will not be liable for any losses incurred or investment(s) made or decisions taken/or not taken based on the information provided herein. Information contained herein does not constitute investment advice or a personal recommendation or take into account the particular investment objectives, financial situations, or needs of individual subscribers. Before acting on any recommendation, subscribers should consider whether it is suitable for their particular circumstances and, if necessary, seek an independent professional advice. This is not directed for access or use by anyone in a country, especially, USA, Canada or the European Union countries, where such use or access is unlawful or which may subject Equitymaster or its affiliates to any registration or licensing requirement. All content and information is provided on an 'As Is' basis by Equitymaster. Information herein is believed to be reliable but Equitymaster does not warrant its completeness or accuracy and expressly disclaims all warranties and conditions of any kind, whether express or implied. Equitymaster may hold shares in the company/ies discussed herein. As a condition to accessing Equitymaster content and website, you agree to our Terms and Conditions of Use, available here. The performance data quoted represents past performance and does not guarantee future results.